JP2022529945A5 - - Google Patents
Info
- Publication number
- JP2022529945A5 JP2022529945A5 JP2021561673A JP2021561673A JP2022529945A5 JP 2022529945 A5 JP2022529945 A5 JP 2022529945A5 JP 2021561673 A JP2021561673 A JP 2021561673A JP 2021561673 A JP2021561673 A JP 2021561673A JP 2022529945 A5 JP2022529945 A5 JP 2022529945A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- mutations
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962835343P | 2019-04-17 | 2019-04-17 | |
| US62/835,343 | 2019-04-17 | ||
| PCT/US2020/028540 WO2020214824A1 (en) | 2019-04-17 | 2020-04-16 | Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529945A JP2022529945A (ja) | 2022-06-27 |
| JP2022529945A5 true JP2022529945A5 (enExample) | 2023-04-24 |
| JP7709384B2 JP7709384B2 (ja) | 2025-07-16 |
Family
ID=72837936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561673A Active JP7709384B2 (ja) | 2019-04-17 | 2020-04-16 | チロシンキナーゼ阻害剤耐性ｅｇｆｒ変異を有するがんに対する化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220175779A1 (enExample) |
| EP (1) | EP3956035A4 (enExample) |
| JP (1) | JP7709384B2 (enExample) |
| KR (1) | KR20220004089A (enExample) |
| CN (1) | CN113993592A (enExample) |
| AU (1) | AU2020257395A1 (enExample) |
| BR (1) | BR112021020601A2 (enExample) |
| CA (1) | CA3132819A1 (enExample) |
| IL (1) | IL287115A (enExample) |
| MX (1) | MX2021012705A (enExample) |
| PH (1) | PH12021552579A1 (enExample) |
| SG (1) | SG11202111120VA (enExample) |
| WO (1) | WO2020214824A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202108311RA (en) | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| PH12021552798A1 (en) | 2019-05-14 | 2022-09-19 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| JP7783182B2 (ja) | 2020-02-12 | 2025-12-09 | ヤンセン バイオテツク，インコーポレーテツド | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 |
| AU2022212123A1 (en) * | 2021-01-29 | 2023-09-07 | Board Of Regents, The University Of Texas System | Methods of treating cancer with kinase inhibitors |
| JP2024505056A (ja) * | 2021-01-29 | 2024-02-02 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ポジオチニブを用いてがんを処置する方法 |
| CA3242316A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| CN115998743B (zh) * | 2023-01-16 | 2024-05-28 | 威尚（上海）生物医药有限公司 | 喹唑啉类化合物在克服奥希替尼耐药中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3120851A1 (en) * | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
| US20190125751A1 (en) * | 2016-05-18 | 2019-05-02 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| MA46852A (fr) * | 2016-11-17 | 2019-09-25 | Univ Texas | Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20 |
| WO2018213770A1 (en) * | 2017-05-19 | 2018-11-22 | Regents Of The University Of Minnesota | Therapeutic methods |
| CA3094108A1 (en) * | 2018-03-27 | 2019-10-03 | Board Of Regents, The University Of Texas Systems | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations |
| CA3101657A1 (en) * | 2018-06-25 | 2020-01-02 | Spectrum Pharmaceuticals, Inc. | Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof |
| US20210346383A1 (en) * | 2018-09-04 | 2021-11-11 | Rain Therapeutics Inc. | Compounds, compositions and methods for treating or preventing her-driven cancers |
| SG11202108311RA (en) * | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| PH12021552110A1 (en) * | 2019-03-29 | 2022-06-06 | Univ Texas | Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions |
| AU2020254499A1 (en) * | 2019-03-29 | 2021-10-28 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 insertions |
-
2020
- 2020-04-16 SG SG11202111120VA patent/SG11202111120VA/en unknown
- 2020-04-16 MX MX2021012705A patent/MX2021012705A/es unknown
- 2020-04-16 BR BR112021020601A patent/BR112021020601A2/pt not_active Application Discontinuation
- 2020-04-16 EP EP20792247.7A patent/EP3956035A4/en active Pending
- 2020-04-16 AU AU2020257395A patent/AU2020257395A1/en not_active Abandoned
- 2020-04-16 CA CA3132819A patent/CA3132819A1/en active Pending
- 2020-04-16 PH PH1/2021/552579A patent/PH12021552579A1/en unknown
- 2020-04-16 US US17/604,560 patent/US20220175779A1/en active Pending
- 2020-04-16 JP JP2021561673A patent/JP7709384B2/ja active Active
- 2020-04-16 KR KR1020217037150A patent/KR20220004089A/ko not_active Ceased
- 2020-04-16 CN CN202080044361.XA patent/CN113993592A/zh active Pending
- 2020-04-16 WO PCT/US2020/028540 patent/WO2020214824A1/en not_active Ceased
-
2021
- 2021-10-10 IL IL287115A patent/IL287115A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529016A5 (enExample) | ||
| JP2022527788A5 (enExample) | ||
| JP7265985B2 (ja) | Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物 | |
| US11291667B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| Ponti et al. | BRAF, NRAS and C-KIT advanced melanoma: clinico-pathological features, targeted-therapy strategies and survival | |
| JP2020502059A5 (enExample) | ||
| JP2021517894A5 (enExample) | ||
| JP2022071099A5 (enExample) | ||
| CN114728005A (zh) | Bi853520在癌症治疗中的用途 | |
| JP2022527499A5 (enExample) | ||
| WO2021259972A1 (en) | Anticancer combination therapy comprising a sos1 inhibitor and a kras g12c inhibitor | |
| WO2017129094A1 (zh) | 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途 | |
| TW202216149A (zh) | 用於治療非小細胞肺癌之ｅｇｆｒ ｔｋｉ | |
| JP2021519306A5 (enExample) | ||
| JP2022515128A5 (enExample) | ||
| Watanabe et al. | The effectiveness of afatinib in a patient with advanced lung adenocarcinoma harboring rare G719X and S768I mutations | |
| ES3054788T3 (en) | Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors | |
| JPWO2013024865A1 (ja) | Ｋｒａｓ遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法 | |
| RU2020134932A (ru) | Соединения с противоопухолевой активностью против раковых клеток, несущих мутации в экзоне 19her2 | |
| WO2022261643A1 (en) | Treating cancers with a cyclin-dependent kinase inhibitor | |
| Grellety et al. | A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy | |
| CN115698338A (zh) | 用妥卡替尼治疗her2突变型癌症的方法 | |
| WO2020239051A1 (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| Ahmed et al. | Therapeutic Insights Into a Case-Control Approach to B-cell Lymphoma 3 (BCL3)-Encoded Protein by Exploring Immune Modulation and Clinical Strategies in Oral Carcinomas | |
| JP7430890B2 (ja) | 置換ブテンアミドの応用 |